Physician profile
Enrique Feoli
NPI 1629097852
$4,859.12
in general payments reported to CMS, 2019-2025
27 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $642 · 2021: $646 · 2022: $670 · 2023: $1,008 · 2024: $476 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.64 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $878.03 | 2019-2024 | |
| Ucb, INC. | $607.67 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $457.34 | 2020-2024 | |
| Greenwich Biosciences, INC. | $440.19 | 2019-2021 | |
| Eisai INC. | $374.16 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $284.95 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $269.53 | 2022-2023 | |
| Neurelis, INC. | $265.69 | 2021-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $175.92 | 2019-2021 | |
| Livanova USA, INC. | $174.38 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $120.76 | 2023 | Aptiom |
| Biocodex, INC. | $113.05 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $82.37 | 2019-2021 | |
| Medtronic, INC. | $79.24 | 2023 | Visualase |
| Aquestive Therapeutics, INC. | $76.20 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aucta Pharmaceuticals, INC. | $66.09 | 2024-2025 | Motpoly Xr |
| Mallinckrodt Enterprises LLC | $64.00 | 2019 | |
| Pyros Pharmaceuticals, INC. | $58.26 | 2024 | Vigpoder |
| Zimmer Biomet Holdings, INC. | $56.67 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $55.38 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $40.34 | 2024 | |
| Arbor Pharmaceuticals, INC. | $32.95 | 2022 | |
| Nobelpharma America, LLC | $24.58 | 2023 | |
| Otter Pharmaceuticals, LLC | $17.24 | 2025 | Sympazan |
| Allergan, INC. | $14.88 | 2020 | |
| Upsher-Smith Laboratories LLC | $14.83 | 2020 | |
| Mallinckrodt Hospital Products INC. | $14.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Feoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.